Skip to main content
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2000 Jan;84(1):72–75. doi: 10.1136/bjo.84.1.72

HLA and Mooren's ulceration

C Taylor 1, S Smith 1, C Morgan 1, S Stephenson 1, T Key 1, M Srinivasan 1, E Cunningham 1, P Watson 1
PMCID: PMC1723219  PMID: 10611103

Abstract

BACKGROUND—Mooren's ulcer is a progressive intractable destructive peripheral ulceration of the cornea, probably of autoimmune aetiology. The disease is rare in the northern hemisphere but is more common in southern and central Africa and the Indian subcontinent. Although rare, its predominance in certain racial groups and their second generation migrants worldwide indicates a genetic as well as a geographic predisposition. The highly polymorphic human leucocyte antigens (HLA) confer genetic susceptibility to several autoimmune disorders. Therefore, a possible link between Mooren's ulcer and HLA type was investigated.
METHODS—Patients (n=22) with non-infective destructive peripheral corneal inflammatory disease were recruited worldwide. Differential diagnosis confirmed Mooren's ulceration in 12 cases. HLA typing (HLA-A, B, C, DRB, DQB) was performed by serology and PCR using sequence specific primers. The patients came from varied ethnic backgrounds and their HLA typing results were compared with published data from ethnically matched control populations.
RESULTS—Of the 12 patients with Mooren's ulcer, 10 (83%) were HLA-DR17(3) positive (including all nine patients of Asian, Indonesian, and black African origin), and 10 (83%) were HLA-DQ2 positive. The frequency of HLA-DR17(3) and DQ2 was higher in the Mooren's ulcer group compared to published data from ethnically matched control populations, where the expected antigen frequencies range between 5% and 40%.
CONCLUSION—These results suggest a possible association between HLA-DR17(3) and/or DQ2 and susceptibility to Mooren's ulcer.



Full Text

The Full Text of this article is available as a PDF (101.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bunce M., O'Neill C. M., Barnardo M. C., Krausa P., Browning M. J., Morris P. J., Welsh K. I. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995 Nov;46(5):355–367. doi: 10.1111/j.1399-0039.1995.tb03127.x. [DOI] [PubMed] [Google Scholar]
  2. Gottsch J. D., Liu S. H. Cloning and expression of bovine corneal antigen cDNA. Curr Eye Res. 1997 Dec;16(12):1239–1244. doi: 10.1076/ceyr.16.12.1239.5029. [DOI] [PubMed] [Google Scholar]
  3. Gottsch J. D., Liu S. H. Cloning and expression of human corneal calgranulin C (CO-Ag). Curr Eye Res. 1998 Sep;17(9):870–874. doi: 10.1076/ceyr.17.9.870.5136. [DOI] [PubMed] [Google Scholar]
  4. Gottsch J. D., Liu S. H., Minkovitz J. B., Goodman D. F., Srinivasan M., Stark W. J. Autoimmunity to a cornea-associated stromal antigen in patients with Mooren's ulcer. Invest Ophthalmol Vis Sci. 1995 Jul;36(8):1541–1547. [PubMed] [Google Scholar]
  5. Gottsch J. D., Stark W. J., Liu S. H. Cloning and sequence analysis of human and bovine corneal antigen (CO-Ag) cDNA: identification of host-parasite protein calgranulin C. Trans Am Ophthalmol Soc. 1997;95:111–129. [PMC free article] [PubMed] [Google Scholar]
  6. Olerup O., Aldener A., Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993 Mar;41(3):119–134. doi: 10.1111/j.1399-0039.1993.tb01991.x. [DOI] [PubMed] [Google Scholar]
  7. Olerup O., Zetterguist H. DR "low-resolution" PCR-SSP typing--a correction and an up-date. Tissue Antigens. 1993 Jan;41(1):55–56. doi: 10.1111/j.1399-0039.1993.tb01979.x. [DOI] [PubMed] [Google Scholar]
  8. Olerup O., Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992 May;39(5):225–235. doi: 10.1111/j.1399-0039.1992.tb01940.x. [DOI] [PubMed] [Google Scholar]
  9. Sangwan V. S., Zafirakis P., Foster C. S. Mooren's ulcer: current concepts in management. Indian J Ophthalmol. 1997 Mar;45(1):7–17. [PubMed] [Google Scholar]
  10. Watson P. G. Management of Mooren's ulceration. Eye (Lond) 1997;11(Pt 3):349–356. doi: 10.1038/eye.1997.74. [DOI] [PubMed] [Google Scholar]
  11. Zegans M. E., Srinivasan M., McHugh T., Whitcher J. P., Margolis T. P., Lietman T., Jennette J. C., Cunningham E. T., Jr Mooren ulcer in South India: serology and clinical risk factors. Am J Ophthalmol. 1999 Aug;128(2):205–210. doi: 10.1016/s0002-9394(99)00162-2. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES